Rna-lipid particles comprising a polysarcosine-lipid conjugate
By using polysarcosine-lipid conjugates to replace PEG to form RNA-lipid particles, the problems of cellular uptake and blood clearance of PEGylated lipid nanoparticles in RNA delivery were solved, achieving more efficient RNA delivery and better safety.
CN122270285APending Publication Date: 2026-06-23EVEREST MEDICINES (CHINA) CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- EVEREST MEDICINES (CHINA) CO LTD
- Filing Date
- 2024-09-20
- Publication Date
- 2026-06-23
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
The present disclosure provides RNA-lipid particles and formulations comprising novel lipids and therapeutic agents, methods of making RNA-lipid particles, and methods of delivering and / or administering RNA-lipid particles. In particular, the present disclosure provides RNA-lipid particles comprising a polyomithine-based lipid conjugate or conjugate of polyomithine and a lipid-like material, and RNA (e.g., single-stranded messenger RNA encoding a peptide or protein of interest), and methods of making RNA-lipid particles. Particles comprising mRNA and polyomithine are delivered to target tissues following administration via intramuscular, intravenous, or subcutaneous routes.
Need to check novelty before this filing date? Find Prior Art